retatrutide fda approval status october 2025 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some Retatrutide Warning: What GLP-1 Providers

Continuous GLP-1RA Use Reduces MACE Risk Incident use of GLP-1RAs was associated with a lower risk of MACE compared to incident use of sulfonylureas

And the more weight they gain, the worse their fertility outcomes are

FDA consumer context worth knowing: The FDA has published consumer guidance expressing concerns about unapproved GLP-1 products marketed for weight loss, including quality and dosing concerns and, in some cases, products that may use semaglutide salt forms that are not the same active ingredient as the FDA-approved reference drug

| Houston Methodist GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more | Harvard Health Semaglutide (oral route) - Side effects & dosage | Mayo Clinic 4 Things to Know Before Trying GLP-1s for Weight Loss | Hartford HealthCare | CT Glucagon-Like Peptide-1 Receptor Agonists - StatPearls | NCBI Bookshelf GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more | Harvard Health Semaglutide-associated kidney injury | Clinical Kidney Journal | Oxford Academic